I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

2025 ASCO® Annual Meeting

We will be contributing to topics related to
-
01:42 PM
Duration 6mins United States
Fixed duration subcutaneous (SC) mosunetuzumab▼ (Mosun) in patients with previously untreated high-tumor burden follicular lymphoma (FL): interim results from the Phase II MorningSun study
Flinn IW, Burke JM, Sharman JP, Anz B, Zuniga R, Tun AM, Jani P, Biondo JML, Wu M, Mun Y, Chopra VS, Farighi R, Lin T, Villasboas JC, Budde LE
02:00 PM
Duration 180mins Chicago, USA
Risk factors (RF) for brain metastases (BM) in patients (pts) with metastatic breast cancer (MBC): An analysis of US electronic health records (EHRs)
Leone JP, Sammons S.L, Lamert P, Huang Y, Montemurro F, Shivhare M, Restuccia E, Knott A, Sanglier T, Tolaney S.M, Lin N.U
Duration 6mins United States
Glofitamab▼ plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2 year (yr) follow up of STARGLO
Abramson JS, Ku M, Hertzberg M, Fox CP, Herbaux C, Huang H-Q, Yoon DH, Kim WS, Zhang H, Abdulhaq H, Townsend W, Mulvihill E, Orellana-Noia V, Ta R, Huang H, Kallemeijn M, Belousov A, Bottos A, Lundberg L, Gregory G
06:30 PM
Duration 180mins Chicago, USA
Krascendo 2: a phase III study of divarasib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previously untreated, advanced or metastatic, KRAS G12C-mutated non-small cell lung cancer (NSCLC)
Skoulidis F, Solomon B, Popat S, Frost N, Heist R, Zhou C, Zarak Crnkovic M, Antic V, Prizant H, Mayo MC Meyenberg C, Keufer-Le Gall S
07:07 PM
Duration 12mins United States
INAVO120 Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2-), endocrine-resistant advanced breast cancer (aBC)
Turner N, Im SA, Saura C, Juric D, Loibl S, Kalinsky K, Schmid P, Loi S, Thanopoulou E, Shankar N, Jin Y, Stout T, Clark T, Song C, Jhaveri K
07:19 PM
Duration 12mins United States
Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2- LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts
Oliveira M, Accordino M, Cervantes A, Gambardella V, Hamilton E, Italiano A, Jhaveri K, Juric D, Kalinsky K, Krop I, Saura C, Schmid P, Turner N C, Varga A, Jin Y, Lim S, Royer-Joo S, Shankar N, Schutzman J, Bedard P
02:00 PM
Duration 180mins Chicago, USA
Meeting diversity enrollment targets in IMbrave152/SKYSCRAPER-14, a global phase 3 study in patients with unresectable hepatocellular carcinoma (HCC)
Cotter C, Bhagat R, Bulhan H, Leon P, Lin L, Richie N, Sims R, Spahn J, Stamatis M, Yalovsky L, Zhu H, Ibrahim Y
Duration 180mins Chicago, USA
Longitudinal Assessment From Liquid Biopsy of Mutations in CD20: A Pilot Study Using a PETE Enrichment Strategy
Tyler Landrith, Linlin Cao, Samantha Smith, Ruben van der Merwe, Corinna Lutterbeck, Carmelo Carlo-Stella, Michael J Dickinson, Martin Hutchings, Ulrich Schlecht, Antonio Sorrentino, Wei Yang, Patrick Bogard, Marina Bacac, Alessia Bottos
06:30 PM
Duration 180mins Chicago, USA
Impact of proton pump inhibitor (PPI) pharmacogenomics (PGx) on toxicities associated with immune checkpoint inhibitor (ICI) therapy
Kennedy LC, Mohindra R, Sharpe JM, Mycroft SL, Balko JM, Chandler SG, Lyalina S
Coming soon